This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Evotec And Yale University Form Open Innovation Alliance

HAMBURG, Germany, Jan. 9, 2013 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) today announced that it has entered into a strategic partnership with Yale University.

Under the agreement, Evotec and Yale intend to leverage first rate science performed at Yale University together with Evotec´s drug discovery infrastructure and expertise into highly innovative discovery approaches in diseases of high unmet medical need. Initially, Evotec and Yale have defined a wide range of scientific fields including metabolic diseases, CNS, immunological diseases and cancer where they will jointly assess and potentially pursue novel assays, screens and models but in particular exploratory drug targets and compounds. The intention is to seamlessly integrate Evotec's drug discovery infrastructure with highly innovative biology at Yale to mature individual projects to a stage where they can be commercialised.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are very excited about this open innovation alliance with Yale. There is a tremendous wealth of scientific innovation at Yale that has the potential to be directly translated into first- and best-in class drug candidates. Together we want to significantly accelerate this process by removing technical bottlenecks and focusing all efforts on bringing individual projects to highest industrial standards in preparation for development and commercialisation partnerships with Pharma companies."

"This agreement is a new collaboration model between academia and the pharmaceutical industry. It essentially gives all faculties at Yale the opportunity to directly translate new biological insights into top notch drug discovery projects. Evotec is uniquely suited as a partner as they combine an extremely broad drug discovery platform with fast processes and proven commercialisation skills", said Dr Jon Soderstrom, Managing Director of Yale's Office of Cooperative Research.

No financials were disclosed.

ABOUT YALE

Founded in 1810, the Yale School of Medicine is a world-renowned centre for biomedical research, education and advanced health care. Among its 27 departments are one of the nation's oldest schools of public health and the internationally recognized Child Study Center, founded in 1911. Yale School of Medicine consistently ranks among the handful of leading recipients of research funding from the National Institutes of Health and other organizations supporting the biomedical sciences. Its core faculty of more than 1,100 physicians and scientists is well represented within the Institute of Medicine and National Academy of Sciences and among investigators of the Howard Hughes Medical Institute.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,374.76 +23.38 0.14%
S&P 500 1,951.13 +2.27 0.12%
NASDAQ 4,733.4970 -16.4820 -0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs